Abstract
Extensive-stage small-cell lung cancer (ES-SCLC) is one of the most lethal malignancies, with a median overall survival of only 8-10 months with first-line chemotherapy despite response rates of 60%-80%. In the second-line setting, the prognosis is even more limited, with only 20%-30% of patients having a response and a median survival measured in weeks to months. This article will review systemic chemotherapy in first- and second-line treatment of patients with ES-SCLC and discuss novel therapeutic agents, cytotoxic and "targeted, " with an emphasis on recently completed clinical trials and ongoing investigations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 262-270 |
| Number of pages | 9 |
| Journal | Clinical Lung Cancer |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2008 |
| Externally published | Yes |
Keywords
- Bortezomib
- Cytotoxic therapy
- Epidermal growth factor
- Etoposide
- Marimastat
- Vandetanib
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pulmonary and Respiratory Medicine